Why Is Immuneering Corp (IMRX) Stock Surpassing 65.57% from Its 50-Day SMA?
Needham has recently reiterated Immuneering Corp (IMRX) stock to Buy rating, as announced on March 15, 2024, according to Finviz. Earlier, on March 15, 2024, TD Cowen had reduced the stock from a Outperform to Market Perform. Jefferies also reduced Hold rating with a price target of $3. Additionally, Needham initiated Buy rating on December […]
Immuneering Corp (IMRX) Stock Rated Buy by Needham
Needham has recently reiterated Immuneering Corp (IMRX) stock to Buy rating, as announced on March 15, 2024, according to Finviz. Earlier, on March 15, 2024, TD Cowen had reduced the stock from a Outperform to Market Perform. Jefferies also reduced Hold rating with a price target of $3. Additionally, Needham initiated Buy rating on December […]
Immuneering Corp (IMRX) Stock: Greater Than Its Current Valuation?
Needham has recently reiterated Immuneering Corp (IMRX) stock to Buy rating, as announced on March 15, 2024, according to Finviz. Earlier, on March 15, 2024, TD Cowen had reduced the stock from a Outperform to Market Perform. Jefferies also reduced Hold rating with a price target of $3. Additionally, Needham initiated Buy rating on December […]
Immuneering Corp (IMRX) Stock: Unveiling Its Hidden Strengths
Needham has recently reiterated Immuneering Corp (IMRX) stock to Buy rating, as announced on March 15, 2024, according to Finviz. Earlier, on March 15, 2024, TD Cowen had reduced the stock from a Outperform to Market Perform. Jefferies also reduced Hold rating with a price target of $3. Additionally, Needham initiated Buy rating on December […]
Immuneering’s (IMRX) Stock Skyrockets in Premarket—A New Dawn for the Struggling Biotech?
In premarket trading on Friday, Immuneering Corporation (Nasdaq: IMRX) witnessed a remarkable surge in its stock price, climbing by 35.66% to reach $1.94. This substantial increase comes in the wake of the company’s announcement of promising initial results from a Phase 2a clinical trial. Here’s an in-depth look at the latest development and how it […]
Needham Issues Buy Rating for Immuneering Corp (IMRX) Stock
Needham has recently reiterated Immuneering Corp (IMRX) stock to Buy rating, as announced on March 15, 2024, according to Finviz. Earlier, on March 15, 2024, TD Cowen had reduced the stock from a Outperform to Market Perform. Jefferies also reduced Hold rating with a price target of $3. Additionally, Needham initiated Buy rating on December […]
Immuneering Corp (IMRX) Stock: Analyzing Its Quiet Power
Needham has recently reiterated Immuneering Corp (IMRX) stock to Buy, as announced on March 15, 2024 according to Finviz. Earlier, on March 15, 2024, TD Cowen had reduced the stock from a Outperform to Market Perform. Jefferies also downgraded from Buy to Hold rating with a price target range from $3 to $16 . Additionally, […]
Immuneering Corp (IMRX) Stock: Analyzing Its Quiet Power
Needham has recently reiterated Immuneering Corp (IMRX) stock to Buy, as announced on March 15, 2024 according to Finviz. Earlier, on March 15, 2024, TD Cowen had reduced the stock from a Outperform to Market Perform. Jefferies also downgraded from Buy to Hold rating with a price target range from $3 to $16. Additionally, Needham […]
It is likely that Immuneering Corp (IMRX) Stock will grow up
Needham lowered the price target for the Immuneering Corp (NASDAQ:IMRX) stock to “a Buy”. The rating was released on March 15, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $3. The stock was initiated by Needham, who disclosed in a […]
The performance of Immuneering Corp (IMRX) Stock has improved
Needham lowered the price target for the Immuneering Corp (NASDAQ:IMRX) stock to “a Buy”. The rating was released on March 15, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $3. The stock was initiated by Needham, who disclosed in a […]
